Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1991-7-25
|
| pubmed:abstractText |
To test the value of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation, we enrolled 12 patients with recurrent non-Hodgkin's lymphoma or Hodgkin's disease having an absolute granulocyte count less than 150 x 10(6)/l on day 30 after autologous hematopoietic stem cell infusion in an open-label, nonrandomized study. These patients were compared to 21 similar historical control patients who were not treated with colony stimulating factor. Overall, the patients treated with granulocyte-macrophage colony stimulating factor had a mean absolute granulocyte count of 704 x 10(6)/l on day 44 after stem cell infusion compared to a mean absolute granulocyte count of 408 x 10(6)/l in historical controls (p = 0.008). The number of documented bacterial and fungal infections occurring after day 30 (9 vs 0, p = 0.01) was significantly reduced in the study group. The toxicity attributed to the granulocyte-macrophage colony stimulating factor was minimal with only one patient experiencing chills. Recombinant human granulocyte-macrophage colony stimulating factor appears to be effective for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic transplantation for lymphoid malignancies, with most patients having accelerated granulocytic recovery and a reduced incidence of infections.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
139-43
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1675592-Adolescent,
pubmed-meshheading:1675592-Adult,
pubmed-meshheading:1675592-Bacterial Infections,
pubmed-meshheading:1675592-Bone Marrow Transplantation,
pubmed-meshheading:1675592-Cell Survival,
pubmed-meshheading:1675592-Child,
pubmed-meshheading:1675592-Child, Preschool,
pubmed-meshheading:1675592-Combined Modality Therapy,
pubmed-meshheading:1675592-Dose-Response Relationship, Drug,
pubmed-meshheading:1675592-Female,
pubmed-meshheading:1675592-Graft Rejection,
pubmed-meshheading:1675592-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:1675592-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:1675592-Hematopoietic Stem Cells,
pubmed-meshheading:1675592-Hodgkin Disease,
pubmed-meshheading:1675592-Humans,
pubmed-meshheading:1675592-Lymphoma, Non-Hodgkin,
pubmed-meshheading:1675592-Male,
pubmed-meshheading:1675592-Middle Aged,
pubmed-meshheading:1675592-Recombinant Proteins,
pubmed-meshheading:1675592-Transplantation, Autologous
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
|
| pubmed:affiliation |
Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330.
|
| pubmed:publicationType |
Journal Article
|